For COVID-19 vaccines with EUA approval from the Philippine FDA, this means the vaccines were found to be safe and effective for the age groups and conditions that the EUA approval provides for.
It should be noted, however, that clinical trials are still ongoing even for vaccine brands which have been granted with an EUA by the Philippine FDA and are being acquired by the government (e.g. Pfizer, AstraZeneca, Sinovac, etc.) since their Phase 3 results have not yet been completed. The analysis of their efficacy has been based on partial/interim Phase 3 clinical trial results, which in this state of a public health emergency will suffice to apply for and be issued with an EUA.
Vaccine developers that applied to have clinical trials in the Philippines have specific objectives for conducting these studies, such as to assess the vaccine in a specific age group or populations not included in initial trials or a different dosing schedule.
All EUA approvals granted, whether locally or in other countries, may be updated as more clinical trial data becomes available.